Brief Definitive Report

Vaccine testing of a recombinant activation-associated secreted protein (ASP1) from Ostertagia ostertagi

P. GELDHOF, Y. MEYVIS, J. VERCRUYSSE & E. CLAEREBOUFT

Laboratory of Parasitology, Faculty of Veterinary Medicine, Ghent University, Salisburylaan, Merelbeke, Belgium

SUMMARY

Previous vaccination trials against the economically important cattle parasite Ostertagia ostertagi have indicated the protective capacity of activation-associated secreted proteins (ASPs). The aim of the current study was to clone and express Oo-asp1 in a baculovirus expression system and to evaluate the protective capacity of the recombinant protein against an O. ostertagi challenge infection in cattle. The full coding sequence of Oo-asp1 was cloned in a baculovirus expression vector in frame with a carboxy-terminal Histidine tag and recombinant virus was used to infect an insect cell culture. Western blot analysis with anti-His and anti-Oo-ASP1 antibodies showed the production of recombinant Oo-ASP1. The cell pellet containing the recombinant was subsequently used to immunize seven calves three times intramuscularly with QuilA as adjuvant. Control animals were solely injected with the QuilA adjuvant. The challenge infection with O. ostertagi consisted of 30 000 L3 larvae per animal given over 30 days (1000 larvae/day, 5 days/week) and started the same day as the final immunization. Immunization with the recombinant Oo-ASP1 did not result in any level of protection against the challenge infection. There was no reduction in faecal egg output or in worm burdens. Moreover, Western blot analyses and ELISA indicated that, although the animals raised an antibody response against the recombinant Oo-ASP1, there was hardly a response against the native Oo-ASP1, suggesting that the baculovirus expressed recombinant was wrongly folded or lacked essential secondary modifications. Further analysis of the structure of the native ASPs and their glycosylations is being done.

Keywords ASP, Ostertagia ostertagi, recombinant, vaccination

RESEARCH NOTE

Previous vaccination trials against the economically important cattle parasite Ostertagia ostertagi have demonstrated the protective capacity of a protein fraction termed ES-thiol (1–3). This antigen fraction is purified from adult excretory-secretory material and is highly enriched for two activation-associated secreted proteins (ASPs), Oo-ASP1 and Oo-ASP2 (4), and cysteine protease activity (1–3). Intramuscular immunization in combination with QuilA as adjuvant consistently resulted in a significant reduction in cumulative faecal egg counts of around 60%. This reduction lasted for about 2 months after the first infection with L3 larvae. In a recent study, Meyvis et al. (3) demonstrated the protective capacity of a purified ASP containing fraction. The ES-thiol fraction was subfractionated by Q-Sepharose anion exchange chromatography to separate the ASPs from the cysteine proteases and other proteins. Three subfractions were obtained, an ‘ASP-enriched’, a ‘cysteine protease-enriched’ and a ‘rest’ fraction. SDS-PAGE analysis, enzyme assays and Western blotting indicated that the ASP-enriched fraction was virtually pure ASPs and free of any cysteine protease activity. Vaccination with this fraction resulted in a 74% reduction in cumulative faecal egg counts and significantly smaller adult male and female worms. It can be anticipated that this level of protection would be sufficient for a commercial vaccine (5). It would protect calves against gastroenteritis during their first grazing season and allow them to develop a natural immunity without production loss. Because it is very difficult to obtain large quantities of
these native ASPs, further development of these antigens into a commercial vaccine will therefore rely on their recombinant expression.

The aim of the current study was to clone and express Oo-aspl in a baculovirus expression system and to evaluate the protective capacity of the recombinant protein against an O. ostertagi challenge infection in cattle.

The full coding sequence of Oo-aspl (4) was cloned in the baculovirus expression vector pVec 35 (Intervet International B.V. Boxmeer, The Netherlands) in frame with a carboxy-terminal Histidine tag. The recombinant baculovirus was constructed by co-transfection of the Oo-aspl pVec 35 vector and a wild-type virus into Sf9 insect cells to promote in vivo recombination. This was essentially done as previously described by Schijns et al. (6). A recombinant virus was isolated, purified and amplified for subsequent infection of an insect cell culture in order to produce the Oo-ASP1 recombinant antigen. Cell supernatant and cell pellet were inactivated with 25 kGray γ-irradiation and run on SDSPAGE gels. A Coomassie stained gel of the supernatant and cell pellet is shown in Figure 1, panel a (lanes 1 and 2). This material was tested for antigen production by Western blotting with conjugated anti-His antibodies and monospecific anti-Oo-ASP1 antibodies (4). The results of these blots are shown in Figure 1, panel a. One band in the cell supernatant and three to four bands in the cell pellet, all around 25 kDa were detected using an anti-His antibody (lanes 3 and 4). A similar pattern was visible using monospecific antibodies against Oo-ASP1 (lanes 5 and 6).

The vaccination trial with the recombinant Oo-ASP1 was essentially done as previously described in Geldhof et al. (1). Fourteen male 7-months-old calves were randomized over two groups of seven animals. The animals were immunized three times by intramuscular injection in the neck at 3-week intervals. One group was administered 100 μg of the Oo-ASP1 containing cell pellet in combination with 750 μg QuilA adjuvant (Superfos Biosector). The control animals were solely injected with the QuilA adjuvant. The challenge infection with O. ostertagi consisted of 30 000 L3 larvae per animal given over 30 days (1000 larvae/day, 5 days/week) and started the same day as the final immunization. The animals were observed daily for adverse reactions to the immunizations and for clinical signs of ostertagiosis. The animals were bled 1 week after each immunization and at the time of necropsy 24 days after the final challenge infection. Faecal egg counts were done three times a week from 20 days after the first challenge infection until necropsy. The faecal egg output was determined using a modified McMaster technique with a sensitivity of 25 eggs per gram (EPG). The cumulative faecal egg output was calculated for each animal as described by Vercruysse et al. (7). At necropsy, the abomasal washings and the abomasal digests were performed as previously.

Figure 1 (a) Protein profile and Western blots of the insect cell supernatant and pellet. Lanes 1 and 2: Coomassie stained gel of cell supernatant and cell pellet, respectively. Lanes 3 and 4: Western blot of cell supernatant and cell pellet developed with anti-His antibody. Lanes 5 and 6: Western blot of cell supernatant and cell pellet developed with anti-Oo-ASP1 antibody (4). (b) Geometric mean of the faecal egg output during the 2-month period of the vaccination trial of the animals vaccinated with QuilA (control) and the animals vaccinated with the recombinant Oo-ASP1 (rec. ASP). (c) Serum antibody response of the animals vaccinated with the recombinant Oo-ASP1 against the cell pellet. Lane 1: pre-immune serum, lane 2: serum taken 1 week after the second immunization. (d) Antibody response in animals vaccinated with the recombinant Oo-ASP1 against the native Oo-ASP1. A native ‘ASP-enriched’ fraction was used to coat the ELISA plate. Serum from the animals vaccinated with the recombinant Oo-ASP1 was compared with the response from animals vaccinated with the native ‘ASP-enriched’ fraction.
Table 1 Numbers of animals per group (n), cumulative faecal egg counts (FEC + range), geometric mean total worms counts (+ range) and percentage L4 stage

<table>
<thead>
<tr>
<th>Group</th>
<th>n</th>
<th>FEC (range)</th>
<th>No. of worms</th>
<th>% L4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>7</td>
<td>2986 (1288–7263)</td>
<td>5771 (2900–8350)</td>
<td>0·3</td>
</tr>
<tr>
<td>Rec. ASP1</td>
<td>7</td>
<td>3173 (1438–5950)</td>
<td>7158 (1700–10 050)</td>
<td>0</td>
</tr>
</tbody>
</table>

Described (1). Two percent of both the abomasal washings and digestes were analysed to determine the worm burden. Geometric mean egg and worm counts were calculated after transformation of the individual counts to ln (count + 1). The significance of differences in the parasitological parameters (cumulative faecal egg counts, worms counts) between the two groups was investigated by a one-tailed Mann–Whitney U-test.

The results of the faecal egg counts during the course of the vaccination trial are shown in Figure 1, panel b as geometric means. During most of the vaccination trial the geometric mean egg counts for the rOo-ASP1 vaccinated animals were higher compared to the control animals. The parasitological data are summarized in Table 1. There was no significant difference in the number of adult worms between the two groups.

The serum antibody responses of the calves to the immunizations were evaluated by Western blotting using sera collected 1 week after the second immunization. Ten micrograms of the recombinant cell pellet was fractionated on 10% SDS-PAGE gels under reducing conditions and subsequently blot transferred to PVDF membranes. After overnight blocking in 10% horse serum in PBS Tween 20 (PBST), the blots were probed for 2 h with pooled sera (diluted 1 : 400 in 2% horse serum PBST), followed by addition of the conjugate (rabbit antibovine HPRO, Sigma) at a 1 : 8000 dilution in 2% horse serum PBST. The immunoreactive antigens were visualized by addition of 0·05% 3,3 diaminobenzidine tetrachloride in PBS containing 0·01% H₂O₂ (v/v). The results are shown in Figure 1, panel c. No antibodies to the antigens were detected in the pre-immune serum (lane 1), while serum taken after the immunization strongly recognized different antigens in the cell pellet, especially a region around 25 kDa, coinciding with the size of the rOo-ASP1 (lane 2). There was no reactivity from serum of the control group (results not shown).

An ELISA was used to measure the presence of cross-reactive antibodies against the native ‘ASP-enriched’ fraction in the animals vaccinated with the baculovirus expressed Oo-ASP1. The ‘ASP-enriched’ antigen fraction was purified as previously described in Meyvis et al. (3) and coated on the ELISA plate at 5 μg/mL with 150 μL/well overnight at 4°C. After three washes with PBST, the plate was blocked with 200 μL/well of 2% horse serum PBST for 2 h at room temperature. The primary antibody, that is, pooled serum from the vaccinated animals, was added at a dilution of 1 : 500 in 2% horse serum PBST. After 2 h at 37°C, the conjugate was added (rabbit antibovine HPRO, Sigma) at a dilution of 1 : 5000 in 2% horse serum PBST and the plate incubated for 2 h at 37°C. o-Phenylenediamine 0·1% in citrate buffer (pH 5·0) served as substrate and optical density (OD) was measured at 492 nm. The OD of the baculo Oo-ASP1 vaccinated animals was compared with the antibody response in animals vaccinated with the native ASP-enriched fraction from a previous vaccination trial (3). The results of the ELISA are shown in Figure 1, panel d. The rOo-ASP1 vaccinated animals showed an OD value of 0·321, which is only 15% of the OD value of animals vaccinated with the native antigens (OD 2·038).

The data presented here indicate that the recombinant version of Oo-ASP1 tested in this study was unable to induce any protection. Moreover, immunization with the recombinant antigen hardly resulted in the production of cross-reactive antibodies against the native version of Oo-ASP1. A possible explanation is that the relative quantities of ASP1 in the insect cell pellet might have been too low to induce a proper cross-reactive antibody response. In the vaccine trial described by Meyvis et al. (3) animals were vaccinated with approximately 30 μg of the native ‘ASP-enriched’ fraction. In the current experiment, a 100-μg of the antigen mixture was injected, a large portion of which are the ASP1 bands. In addition, the Western blot analysis indicated that the immunized animals strongly recognized the recombinant ASP1 bands. It is therefore questionable if vaccinating with a higher dose would increase the titre of cross-reactive antibodies and subsequently induce protection. Alternatively, the baculovirus expressed recombinant could be wrongly folded or lack essential secondary modifications and might therefore not induce cross-reactive antibodies. The baculovirus expression system has previously been successfully used to express host-protective antigens from Fasciola hepatica (8), Schistosoma japonicum (9) and Ancylostoma caninum (10). However, it was never used to express a nematode ASP molecule. All previously tested ASP recombinants were bacterial and/or yeast expressed versions. This was the case for ASPs from hookworms (11–14), Haemonchus contortus (15) and Onchocerca volvulus (16). In the case of the O. ostertagi ASP, a bacterially expressed Oo-ASP1 previously proved to be insoluble and could not be refolded or solubilized (Y. Meyvis, unpublished results), most likely due to the high cysteine content in this type of molecules (4). A further analysis of the structure of the native ASPs and their glycosylations is being done. It will investigate the peptide and/or glycan epitopes that are important for the protection. On the other hand, it is important to note that the native
ASP fraction consisted of two ASPs, that is, ASP1 and ASP2. Although ASP1 is far more abundant in the protective fraction and shares similarity with ASP2, it may very well be that ASP2 or a mix of both molecules is required for the protection.

ACKNOWLEDGEMENTS

P.G. is a recipient of Marie Curie EU reintegration grant (No. 028870) and is a Postdoctoral Fellow of the Fund for Scientific Research – Flanders (Belgium) (F.W.O. – Vlaanderen). Y.M. is supported by a grant from Ghent University (BOF 01109405). This work was partly financed by Intervet International B.V. We thank V. De Maere, I. Vercauteren and S. Casaert for their assistance.

REFERENCES